Infliximab

(Remicade®)

Infliximab

Drug updated on 8/25/2023

Dosage FormInjection (intravenous; 100 mg)
Drug ClassTumor necrosis factor (TNF) blocker
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for Crohn’s Disease: reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy, and reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing disease.
  • Indicated for pediatric Crohn’s Disease: reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active disease who have had an inadequate response to conventional therapy.
  • Indicated for ulcerative colitis: reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy.
  • Indicated for pediatric ulcerative colitis: reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active disease who have had an inadequate response to conventional therapy.
  • Indicated for rheumatoid arthritis in combination with methotrexate: reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active disease.
  • Indicated for psoriatic arthritis: reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in adult patients.
  • Indicated for plaque psoriasis: treatment of adult patients with chronic severe (i.e., extensive and/or disabling) plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate.
  • Indicated for ankylosing spondylitis: reducing signs and symptoms in adult patients with active disease.

Product Monograph / Prescribing Information

Document TitleYearSource
REMICADE (infliximab) Prescribing Information.2021Janssen Biotech, Inc. Horsham, PA

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Comparison of infliximab with adalimumab for the treatment of non-infectious uveitis: a systematic review and meta-analysis.2023BMC Opthalmology
Systematic review and meta-analysis: loss of response and need for dose escalation of infliximab and adalimumab in ulcerative colitis.2022Inflammatory Bowel Disease
Infliximab in hidradenitis suppurativa: a systematic review and meta-analysis.2022Dermatologic Therapy
A systematic review on infliximab biosimilar SB2: from pre-clinical data to real-world evidence.2022Expert Opinion on Biological therapy
Infliximab as a second-line therapy for children with refractory Kawasaki disease: a systematic review and meta-analysis of randomized controlled trials.2022British Journal of Clinical Pharmacology
Efficacy and tolerability of infliximab retreatment in patients with inflammatory bowel disease: a systematic review and meta-analysis.2021Therapeutic Advances in Chronic Disease
Efficacy of infliximab in the treatment of Kawasaki disease: a systematic review and meta-analysis.2021Experimental and Therapeutic Medicine
Efficacy of infliximab in treatment-resistant depression: a systematic review and meta-analysis.2020Pharmacology Biochemistry and Behaviour
Comparable long-term outcomes of cyclosporine and infliximab in patients with steroid-refractory acute severe ulcerative colitis: a meta-analysis.2020Frontiers in Medicine
Etrolizumab versus infliximab in the treatment of induction phase of ulcerative colitis: a systematic review and indirect comparison.2019Pharmacological Research
Infliximab clinically treating ulcerative colitis: a systematic review and meta-analysis.2019Pharmacological Research
Systematic review: efficacy and safety of accelerated induction regimes in infliximab rescue therapy for hospitalized patients with acute severe colitis.2018Digestive Diseases and Sciences
Meta-analysis: the influence of preoperative infliximab use on postoperative complications of Crohn’s disease.2018Inflammatory Bowel Diseases

Clinical Practice Guidelines